Literature DB >> 16291764

Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.

Myriam Arévalo-Herrera1, Yezid Solarte, María Fernanda Yasnot, Angélica Castellanos, Adriana Rincón, Allan Saul, Jianbing Mu, Carole Long, Louis Miller, Sócrates Herrera.   

Abstract

Aotus monkeys were used to determine the immunogenicity of Pvs25 protein expressed in the zygote/ookinete surface. Animals were immunized in three times with 100 microg of Pvs25 formulated in Montanide ISA-720. Antibodies to Pvs25 detected by an enzyme-linked immunosorbent assay appeared by day 30 after the first immunization, with a peak of antibodies levels on day 150. These antibodies were still detectable on day 300. Plasma samples on day 150 from experimental group were able to completely block the development of the parasite in Anopheles albimanus mosquitoes artificially fed with human isolates of Plasmodium vivax. Immunized Aotus monkeys were infected with blood forms of the P. vivax Salvador I strain and no boosting effect of blood infection on titers of antibodies to Pvs25 was observed despite the presence of infective gametocytes. In conclusion, Pvs25 protein formulated in Montanide ISA-720 induces efficient and long-lasting transmission-blocking antibodies that cannot be boosted by parasite infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291764     DOI: 10.4269/ajtmh.2005.73.32

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

Review 1.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 2.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

3.  Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Authors:  Sócrates Herrera; Olga Lucía Fernández; Omaira Vera; William Cárdenas; Oscar Ramírez; Ricardo Palacios; Mario Chen-Mok; Giampietro Corradin; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors.

Authors:  Sócrates Herrera; Olga Fernández; María R Manzano; Bermans Murrain; Juana Vergara; Pedro Blanco; Ricardo Palacios; Juan D Vélez; Judith E Epstein; Mario Chen-Mok; Zarifah H Reed; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

Review 5.  Flipping the paradigm on malaria transmission-blocking vaccines.

Authors:  Rhoel R Dinglasan; Marcelo Jacobs-Lorena
Journal:  Trends Parasitol       Date:  2008-07-01

Review 6.  Acquired immunity to malaria.

Authors:  Denise L Doolan; Carlota Dobaño; J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

7.  Recombinant Pvs48/45 antigen expressed in E. coli generates antibodies that block malaria transmission in Anopheles albimanus mosquitoes.

Authors:  Myriam Arévalo-Herrera; Andrés F Vallejo; Kelly Rubiano; Yezid Solarte; Catherin Marin; Angélica Castellanos; Nora Céspedes; Sócrates Herrera
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

8.  Optimization of a Membrane Feeding Assay for Plasmodium vivax Infection in Anopheles albimanus.

Authors:  Andrés F Vallejo; Kelly Rubiano; Andres Amado; Amy R Krystosik; Sócrates Herrera; Myriam Arévalo-Herrera
Journal:  PLoS Negl Trop Dis       Date:  2016-06-29

Review 9.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

10.  Immunoreactivity of Sera From Low to Moderate Malaria-Endemic Areas Against Plasmodium vivax rPvs48/45 Proteins Produced in Escherichia coli and Chinese Hamster Ovary Systems.

Authors:  Myriam Arévalo-Herrera; Kazutoyo Miura; Nora Cespedes; Carlos Echeverry; Eduardo Solano; Angélica Castellanos; Juan Sebastián Ramirez; Adolfo Miranda; Andrey V Kajava; Carole Long; Giampietro Corradin; Sócrates Herrera
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.